title: 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract.
abstract: Recent data suggest that functional receptors (R) for vasoactive intestinal peptide (VIP) are expressed on various tumor cells. The high-level expression of VIPR on tumor cells provided the basis for the successful use of 123I-labeled VIP for the in vivo localization of intestinal adenocarcinomas and endocrine tumors. We here report an update of our imaging results using 123I-VIP (150-200 MBg/1 microgram/patient) in 169 patients. In patients with pancreatic adenocarcinomas without liver metastases, the primary/recurrent tumor was visualized in 16 of 18 patients (89%) and liver metastases were imaged in 15 of 16 patients. In 11 of 12 patients with colorectal adenocarcinomas, the primary/recurrent tumor (92%) was imaged by 123I-VIP. Also, in 21 of 25 patients, liver metastases (84%); in 3 of 6 patients, lung metastases (50%); and in 4 of 5 patients, lymph-node metastases (80%) were imaged by 123I-VIP. In 10 of 10 patients with gastric adenocarcinomas, the primary/recurrent tumor; in 3 of 4 patients, liver metastases; and in 2 of 2 patients, lymph-node metastases were visualized by 123I-VIP. 123I-VIP localized primary intestinal carcinoid tumors in 15 of 17 patients (88%) and 8 of 10 primary insulinomas (80%). We conclude that the 123I-VIPR scintigraphy localizes intestinal adenocarcinomas and endocrine tumors as well as metastatic tumor sites.
authors.affiliation: Department of Nuclear Medicine, University of Vienna, Austria.
authors.forename: I
authors.initials: I
authors.lastname: Virgolini
authors.forename: M
authors.initials: M
authors.lastname: Raderer
authors.forename: A
authors.initials: A
authors.lastname: Kurtaran
authors.forename: P
authors.initials: P
authors.lastname: Angelberger
authors.forename: Q
authors.initials: Q
authors.lastname: Yang
authors.forename: M
authors.initials: M
authors.lastname: Radosavljevic
authors.forename: M
authors.initials: M
authors.lastname: Leimer
authors.forename: K
authors.initials: K
authors.lastname: Kaserer
authors.forename: S R
authors.initials: SR
authors.lastname: Li
authors.forename: G
authors.initials: G
authors.lastname: Kornek
authors.forename: P
authors.initials: P
authors.lastname: Hübsch
authors.forename: B
authors.initials: B
authors.lastname: Niederle
authors.forename: J
authors.initials: J
authors.lastname: Pidlich
authors.forename: W
authors.initials: W
authors.lastname: Scheithauer
authors.forename: P
authors.initials: P
authors.lastname: Valent
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000648:ultrastructure*; D000595:Amino Acid Sequence; D000818:Animals; D019556:COS Cells / Q000000981:diagnostic imaging / Q000648:ultrastructure; D004701:Endocrine Gland Neoplasms / Q000000981:diagnostic imaging* / Q000648:ultrastructure*; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging* / Q000648:ultrastructure*; D006801:Humans; D007457:Iodine Radioisotopes; D008969:Molecular Sequence Data; D011869:Radioligand Assay; D011877:Radionuclide Imaging; D018005:Receptors, Vasoactive Intestinal Peptide / Q000032:analysis* / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism*
chemical_list: D007457:Iodine Radioisotopes; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide